Skip to search formSkip to main contentSkip to account menu

SDX 308

Known as: SDX-308, SDX308 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

CEP 18082

Broader (1)

Heterocyclic Compounds, 3-Ring

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies
Non-steroidal anti-inflammatory drugs (NSAIDs) comprise the group of structurally diverse but similarly acting compounds that are… 
Highly Cited
2007
Highly Cited
2007
SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.
Multiple myeloma is characterized by increased osteoclast activity that results in bone destruction and lytic lesions. With the… 
2007
2007
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway
We have reported previously that R-enantiomer of etodolac (R-etodolac), which is under investigation in phase 2 clinical trials… 
2007
2007
R-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells
AbstractObjectiveSDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac… 
Review
2007
Review
2007
Treatment of multiple myeloma with SDX-308.
Multiple myeloma (MM) is a hematologic malignancy characterized by dysregulated proliferation of plasma cells and increased… 
2007
2007
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro
SummarySDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-etodolac) which has anti-tumour activity unrelated to… 
2006
2006
SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.
Multiple myeloma (MM) is characterized by increased osteoclast activity resulting in bone destruction and the development of… 
2006
2006
Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.
In a previous study we reported that R-enantiomer of etodolac (R-etodolac) which is under investigation in Phase II clinical… 
2005
2005
R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.
SDX-101, the less toxic R-isomer of the commercially available non-steroidal inflammatory drug R,S-etodolac (Lodine®), lacks COX… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)